Abiopharma

New Form 8-K - Barinthus Biotherapeutics plc. Filed: 2025-08-07 AccNo: 0001828185-25-000058 Size: 386 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Silence Therapeutics plc Filed: 2025-08-07 AccNo: 0000950170-25-104593 Size: 8 MB

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

New Form 8-K - Whitehawk Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104592 Size: 621 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Edgewise Therapeutics - Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

New Form 8-K - Perimeter Solutions, Inc. Filed: 2025-08-07 AccNo: 0001880319-25-000103 Size: 473 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - PepGen Inc. Filed: 2025-08-07 AccNo: 0001193125-25-174982 Size: 262 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - UroGen Pharma Ltd. Filed: 2025-08-07 AccNo: 0001437749-25-025242 Size: 259 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Edgewise Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001104659-25-074987 Size: 296 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

[Press Release] HUTCHMED Reports 2025 Interim Results

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

UroGen Pharma Expands Commercial Portfolio with Launch ofZUSDURI™ and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments